Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,510.00
Bid: 12,524.00
Ask: 12,526.00
Change: 118.00 (0.95%)
Spread: 2.00 (0.016%)
Open: 12,468.00
High: 12,556.00
Low: 12,434.00
Prev. Close: 12,392.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Astrazeneca Plc

21 May 2014 12:34

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Identity of the person whose positions/dealings are being disclosed: Invesco Limited
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Astrazeneca Plc
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e) Date position held/dealing undertaken: 20 May 2014
(f) Has the discloser previously disclosed, or are they today disclosing, under the Code in respect of any other party to this offer? YES

If YES, specify which: Pfizer Inc

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

GB0009895292

Astrazeneca Ord USD 0.25

Interests Short positions
Number % Number %
(1) Relevant securities owned and/or controlled: 44,107,263 3.49
(2) Derivatives (other than options):
(3) Options and agreements to purchase/sell:

TOTAL:

44,107,263 3.49

All interests and all short positions should be disclosed.

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other executive options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1©, copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

(46) Purchases and sales

Class of relevant security Purchase/sale Number of securities Price per unit
Ord USD 0.25 Sale 10,890 42.99 GBP
Ord USD 0.25 Sale 809,656 43.00 GBP
Ord USD 0.25 Sale 500,000 42.07 GBP

(b) Derivatives transactions (other than options)

Class of relevant security Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities Price per unit

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type

e.g. American, European etc.

Expiry date Option money paid/ received per unit

(ii) Exercising

Class of relevant security Product description

e.g. call option

Number of securities Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing

e.g. subscription, conversion

Details Price per unit (if applicable)

The currency of all prices and other monetary amounts should be stated.

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state “none”

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached? NO
Date of disclosure: 21 May 2014
Contact name: Philippa Sadler
Telephone number: 01491 417 447

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Copyright Business Wire 2014

Date   Source Headline
29th Aug 20197:00 amRNSAnifrolumab Phase III trial meets primary endpoint
28th Aug 20197:05 amRNSFasenra granted US Orphan Drug Designation for
28th Aug 20197:00 amRNSBreztri Aerosphere Phase III ETHOS trial met
22nd Aug 20197:00 amRNSRoxadustat approved in China for the treatment of
22nd Aug 20197:00 amRNSAstraZeneca agrees to buy US FDA Priority Review
21st Aug 20197:00 amRNSUpdate on the Phase III NEPTUNE trial
20th Aug 20197:00 amRNSFarxiga met primary endpoint in landmark Phase III
19th Aug 20197:00 amRNSDirectorate Change
14th Aug 20197:00 amRNSLynparza Phase III PAOLA-1 trial met primary endpo
14th Aug 20197:00 amRNSCalquence granted US Breakthrough Therapy Designat
9th Aug 20199:28 amRNSAmendment: Tagrisso significantly improves overall
9th Aug 20197:00 amRNSTagrisso significantly improves overall survival
7th Aug 20197:00 amRNSLynparza Phase III PROfound trial in HRR*
5th Aug 20197:00 amRNSForxiga label updated in the EU in type-2 diabetes
1st Aug 20193:00 pmRNSTotal Voting Rights
25th Jul 20197:00 amRNSAZN: H1 2019 Results
15th Jul 20197:00 amRNSUpdate on US regulatory decision for Farxiga
12th Jul 20197:00 amRNSImfinzi granted US Orphan Drug Designation for
1st Jul 20193:00 pmRNSTotal Voting Rights
1st Jul 20197:00 amRNSForxiga receives positive EU CHMP opinion for
1st Jul 20197:00 amRNSFasenra receives positive EU CHMP opinion for self
27th Jun 20197:00 amRNSImfinzi improves overall survival at interim
19th Jun 20197:00 amRNSBreztri Aerosphere (PT010) approved in Japan for
19th Jun 20197:00 amRNSLynparza approved in Japan for 1st-line
19th Jun 20197:00 amRNSBevespi Aerosphere approved by the Japanese
18th Jun 20197:00 amRNSLynparza approved in the EU for 1st-line
17th Jun 20197:00 amRNSCalquence significantly prolonged the time patient
12th Jun 20194:45 pmRNSPublication of a Prospectus
6th Jun 20197:00 amRNSCalquence Phase III ELEVATE-TN trial met primary
5th Jun 201912:36 pmEQSHardman & Co Research: AstraZeneca: Where has all the cash gone?
3rd Jun 20193:00 pmRNSBlock listing Interim Review
3rd Jun 20193:00 pmRNSTotal Voting Rights
3rd Jun 20197:00 amRNSLynparza nearly doubled time patients lived with
10th May 20197:00 amRNSPooled analyses of the roxadustat global Phase III
8th May 20192:00 pmRNSDirector/PDMR Shareholding
8th May 201911:00 amRNSDirector Declaration
8th May 20197:00 amRNSTrastuzumab deruxtecan demonstrated clinically
7th May 20197:00 amRNSCalquence PhIII ASCEND trial met primary endpoint
3rd May 20197:00 amRNSQternmet XR approved in the US for type-2 diabetes
1st May 20193:00 pmRNSTotal Voting Rights
1st May 201912:00 pmRNSDirector/PDMR Shareholding
29th Apr 20197:00 amRNSLynparza receives positive EU CHMP opinion for 1st
26th Apr 20195:45 pmRNSResult of AGM
26th Apr 20197:00 amRNSAZN: Q1 2019 Results
10th Apr 20197:00 amRNSLynparza approved in EU for the treatment of germl
9th Apr 20194:10 pmEQSHardman & Co Research: Global Pharmaceuticals: 2018 industry sales
4th Apr 20191:30 pmRNSHolding(s) in Company
3rd Apr 201910:00 amRNSDirector/PDMR Shareholding
2nd Apr 20193:00 pmRNSTotal Voting Rights
1st Apr 20196:00 pmRNSAstrazeneca

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.